What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?

BJU International
Alain RuffionPhilippe Grise

Abstract

To assess the effects of two doses of botulinum toxin A (Dysport, Ipsen-Biotech, France; 500 and 1000 Speywood units, SU) injected into the bladder for treating incontinence due to a neurogenic overactive bladder. In an open-label, prospective study between October 2002 and May 2004, in two centres, we analysed the effects of successive doses of 500 and 1000 SU of Dysport, endoscopically injected into the detrusor muscle. At each step, patients (26 women and 19 men) were re-evaluated at 1 month (clinical evaluation and pressure-flow study). If there was a 'good' clinical response (complete absence of urinary leakage) the patient was observed until incontinence recurred; otherwise a further injection was administered at a higher dose. The mean (sd, range) follow-up was 22 (0.75, 5-31) months; 11 of the 45 patients (24%) did not respond primarily at 1 month for both doses. The analysis of the two curves of survival with no re-injection of Dysport showed a statistically longer action at 1000 SU (P = 0.016). However, in this group there was one patient with general muscle weakness and asthenia, which could have been related to the injection. The optimum dose of Dysport for incontinence secondary to a neurogenic overactive bladder i...Continue Reading

References

Jan 1, 1988·Movement Disorders : Official Journal of the Movement Disorder Society·A B Scott, D Suzuki
Oct 12, 2000·The Journal of Urology·K J WeldR R Dmochowski
Apr 12, 2002·Neurourology and Urodynamics·Werner SchäferUNKNOWN International Continence Society
Oct 2, 2002·Current Urology Reports·Christopher P SmithMichael B Chancellor

❮ Previous
Next ❯

Citations

Mar 7, 2008·Journal of Neural Transmission·A Apostolidis, C J Fowler
Jul 14, 2010·Current Urology Reports·Christopher S GomezAngelo Gousse
Jul 7, 2007·Nature Clinical Practice. Urology·Arun SahaiUNKNOWN GKT Botulinum Study Group
Jan 24, 2014·International Journal of MS Care·Gael J YonnetJohn W Rose
Jun 15, 2007·Current Opinion in Urology·Donna J Sellers, Neil McKay
Feb 4, 2011·Expert Opinion on Pharmacotherapy·Apostolos Apostolidis
Mar 6, 2010·Scandinavian Journal of Urology and Nephrology·Mohammadreza NikoobakhtGholamreza Pourmand
Apr 22, 2015·International Urology and Nephrology·Mazen AlsinnawiJohn Thornhill
Apr 22, 2017·Neurourology and Urodynamics·Florie BottetUNKNOWN Groupe d'Etude de Neuro-Urologie de Langue Française (GENULF) and the committee of NeuroUrology of the French Association of
May 10, 2007·International Braz J Urol : Official Journal of the Brazilian Society of Urology·David E RappGregory T Bales
Jun 22, 2011·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·V BridouxJ-J Tuech

❮ Previous
Next ❯

Related Concepts

Related Feeds

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.